Back

Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials

26 August 2023 (16:20 - 16:30)
Organised by: Logo
Congress Presentation Part of: Insights from recent HFpEF trials 1 Biomarkers ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Mikhail Sumin

Mainz (Germany)

5 More presentations in this session

Presentation thumbnail
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Doctor S. Chatur (Boston, US)
Abstract Slides Video
Presentation thumbnail
Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials
Doctor X. Wang (Boston, US)
Abstract Slides Video
Presentation thumbnail
Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF
Professor C. Saldarriaga (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF
Professor B. Pitt (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction
Doctor M. Pabon (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Insights from recent HFpEF trials 1
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 16:20 CET
You may be interested in
thumbnail
Congress Session
Insights from recent HFpEF trials 1
thumbnail
Congress Presentation
Diagnostic and prognostic use of circulating biomarkers of fibrosis
thumbnail
Congress Presentation
EMPEROR-Preserved: association of echocardiographic features of diastolic dysfunction with the clinical efficacy of empagliflozin in HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources